Skip to main content

Pelthos Therapeutics Inc.

PTHS
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001919246

In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Pelthos Therapeutics Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of PTHS: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders54−1
Shares83.9K25.0K−58.9K (−70.2%)
Value$59.6K$16.0K−$43.6K (−73.1%)

New holders (0)

Institutions that held Pelthos Therapeutics Inc. at the end of Q4 2024 but not at the end of Q3 2024.

None.

Sold out (1)

Institutions that held Pelthos Therapeutics Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of PTHS in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Avantax Planning Partners, Inc.47,205$33.5K